Profil
Katherine Takaki is currently Senior Vice President-Global Regulatory Affairs at Trevi Therapeutics, Inc. Formerly, Dr. Takaki was Group Director & Head-Regulatory Strategy at Bristol Myers Squibb Co. and VP-Global Regulatory Affairs at Iterum Therapeutics Plc.
Education includes a doctorate from Massachusetts Institute of Technology and an undergraduate degree from the University of Hawai'i at Hilo.
Postes actifs de Katherine Takaki
| Sociétés | Poste | Début |
|---|---|---|
| TREVI THERAPEUTICS, INC. | Conseiller Juridique Général | - |
Anciens postes connus de Katherine Takaki
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| ITERUM THERAPEUTICS PLC | Conseiller Juridique Général | - |
Formation de Katherine Takaki
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Hawai'i at Hilo
University of Hawai'i at Hilo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Iterum Therapeutics Plc
Iterum Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem | Health Technology |
















